Reactivating p53 mutants selectively in patients.

Abstract excerpt

As the most frequently mutated protein across cancers, the tumor suppressor protein p53 is inactivated by the most extensive array of different mutations. Targeting a frequent p53 mutant with the reactivator rezatapopt, recent findings published in the New England Journal of Medicine mark an encouraging step toward clinical utility.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Neoplasms
• Share to Tumor Suppressor Protein p53